Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Durect Corp (DRRX)

Durect Corp (DRRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,243
  • Shares Outstanding, K 31,036
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -27,620 K
  • 60-Month Beta 0.85
  • Price/Sales 3.19
  • Price/Cash Flow N/A
  • Price/Book 1.58
Trade DRRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.65
  • Most Recent Earnings $-0.27 on 03/27/24
  • Latest Earnings Date 05/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 167.29% ( -143.81%)
  • Historical Volatility 122.02%
  • IV Percentile 71%
  • IV Rank 28.73%
  • IV High 562.12% on 10/19/23
  • IV Low 8.12% on 01/03/24
  • Put/Call Vol Ratio 0.33
  • Today's Volume 20
  • Volume Avg (30-Day) 123
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 6,205
  • Open Int (30-Day) 5,942

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.21
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7235 +24.40%
on 04/15/24
1.3400 -32.84%
on 03/27/24
-0.2800 (-23.73%)
since 03/19/24
3-Month
0.6802 +32.31%
on 02/07/24
1.4400 -37.50%
on 03/15/24
+0.1679 (+22.93%)
since 01/19/24
52-Week
0.4703 +91.37%
on 11/10/23
7.4600 -87.94%
on 05/22/23
-3.7700 (-80.73%)
since 04/19/23

Most Recent Stories

More News
Durect: Q4 Earnings Snapshot

Durect: Q4 Earnings Snapshot

DRRX : 0.8813 (-3.15%)
Durect: Q3 Earnings Snapshot

Durect: Q3 Earnings Snapshot

DRRX : 0.8813 (-3.15%)
DURECT Corporation Announces Presentations in Upcoming Investor Conferences

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 0.8813 (-3.15%)
Durect: Q2 Earnings Snapshot

Durect: Q2 Earnings Snapshot

DRRX : 0.8813 (-3.15%)
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update....

DRRX : 0.8813 (-3.15%)
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 0.8813 (-3.15%)
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the...

DRRX : 0.8813 (-3.15%)
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and...

DRRX : 0.8813 (-3.15%)
Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

DRRX : 0.8813 (-3.15%)
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 0.8813 (-3.15%)
BVS : 4.50 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

3rd Resistance Point 1.0307
2nd Resistance Point 0.9853
1st Resistance Point 0.9477
Last Price 0.8813
1st Support Level 0.8647
2nd Support Level 0.8193
3rd Support Level 0.7817

See More

52-Week High 7.4600
Fibonacci 61.8% 4.7899
Fibonacci 50% 3.9652
Fibonacci 38.2% 3.1404
Last Price 0.8813
52-Week Low 0.4703

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar